Calliditas announces exclusive in-licensing related to autoimmune hepatitis in the US market.

NORDIC BUSINESS REPORT-August 13, 2019-Calliditas announces exclusive in-licensing related to autoimmune hepatitis in the US market

(C)2019 M2 COMMUNICATIONS http://www.m2.com

Calliditas Therapeutics AB (Calliditas) (STO:CALTX), a specialty pharmaceutical company, announced on Monday the exclusive in-licensing of Budenofalk 3mg oral capsule for the US market from the German pharmaceutical company Dr. Falk Pharma GmbH (Dr. Falk), a leading company in gastroenterology.

This deal has an initial upfront payment of EUR1.5m and foresees additional regulatory related payments, subject to market approval from the US Food and Drug Administration (FDA). The total deal value amounts to EUR40m, including future sales milestones and comes with typical royalties.

This agreement covers all indications for the US market, excluding orphan indications outside of liver targets.

Initially, Calliditas will leverage Dr. Falk's clinical trial data and expertise in liver indications, such as...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT